Clinical and molecular surveillance of artemisinin resistant falciparum malaria in Myanmar (2009–2013)

Myat Htut Nyunt1,2, Myat Thu Soe2, Hla Win Myint3, Htet Wai Oo2, Moe Moe Aye2, Soe Soe Han2, Ni Ni Zaw2, Cho Cho2, Phyoe Zaw Aung2, Khin Thiri Kyaw2, Thin Thin Aye2, Naychi Aung San2, Leonard Ortega4, Krongthong Thimasarn5, Maria Dorina G. Bustos6, Sherwin Galit7, Mohammad Rafiul Hoque1, Pascal Ringwald4, Eun-Taek Han1*† and Myat Phone Kyaw2†

Abstract

Background: Emergence of artemisinin-resistant malaria in Southeast Asian countries threatens the global control of malaria. Although K13 kelch propeller has been assessed for artemisinin resistance molecular marker, most of the mutations need to be validated. In this study, artemisinin resistance was assessed by clinical and molecular analysis, including k13 and recently reported markers, pfarps10, pffd and pfmdr2.

Methods: A prospective cohort study in 1160 uncomplicated falciparum patients was conducted after treatment with artemisinin-based combination therapy (ACT), in 6 sentinel sites in Myanmar from 2009 to 2013. Therapeutic efficacy of ACT was assessed by longitudinal follow ups. Molecular markers analysis was done on all available day 0 samples.

Results: True recrudescence treatment failures cases and day 3 parasite positivity were detected at only the southern Myanmar sites. Day 3 positive and k13 mutants with higher prevalence of underlying genetic foci predisposing to become k13 mutant were detected only in southern Myanmar since 2009 and comparatively fewer mutations of pfarps10, pffd, and pfmdr2 were observed in western Myanmar. K13 mutations, V127M of pfarps10, D193Y of pffd, and T448I of pfmdr2 were significantly associated with day 3 positivity (OR: 6.48, 3.88, 2.88, and 2.52, respectively).

Conclusions: Apart from k13, pfarps10, pffd and pfmdr2 are also useful for molecular surveillance of artemisinin resistance especially where k13 mutation has not been reported. Appropriate action to eliminate the resistant parasites and surveillance on artemisinin resistance should be strengthened in Myanmar.

Keywords: Drug resistance, Falciparum, Malaria, Myanmar, Kelch 13, Artemisinin

Background

Artemisinin-based combination therapy (ACT) is the only recommended mainstream treatment for falciparum malaria in almost all endemic countries [1]. Decreased susceptibility of artemisinin was first reported in Cambodia [2], followed by Thailand [3] and Myanmar [4]. As of 2015, artemisinin-resistant falciparum malaria has been documented in 5 of the Greater Mekong countries: Cambodia, Laos People’s Democratic Republic, Myanmar, Thailand, and Vietnam [5]. As drug-resistant malaria has emerged, therapeutic efficacy studies have been conducted in almost all the endemic countries, initiated by the World Health Organization (WHO) [6].

In Myanmar, artemether–lumefantrine, artesunate–mefloquine or dihydroartemisinin–piperaquine has been deployed for treatment of falciparum malaria since 2002...
and delayed parasite clearance after treatment with ACT has been observed since 2009 [5]. Although the trend of malaria morbidity and mortality has been decreasing in Myanmar, malaria is still one of the top priority diseases and endemic in 284 out of 330 townships, as of 2014 [8].

After discovery of K13 kelch propeller artemisinin resistance molecular marker, many studies showed the prevalence of k13 mutations in falciparum-endemic countries, including Myanmar [9–11]. Although independent emergence of the k13 mutation was suggested [12], artemisinin resistance-associated k13 mutations were detected only in Southeast Asian countries [13] but most of the k13 mutations have not yet validated. Evidence of independent emergence of artemisinin resistance in several areas in the Greater Mekong Sub-region led to a change in strategy from containment to elimination of multi-drug resistant falciparum in the region [14]. Previous cross-sectional k13 surveys in Myanmar covered most of the country, except southern Myanmar, and indicated widespread k13 mutations across the country with high prevalence of k13 mutants in northwestern Myanmar near the border areas with India [10]. Another independent cohort study in Myanmar [9] showed a lack of day 3 parasite positivity and no artemisinin resistance-associated k13 mutations in Chin State, next to the border with Bangladesh. At the same time, no k13 mutation was reported in Bangladesh [15] and India [16].

In this study, the efficacy of first-line anti-malarials in 6 sentinel sites was assessed by clinical follow-up and molecular marker analysis to confirm and validate the observed k13 mutations for delayed parasite clearance. Moreover, newly identified molecular markers from genome-wide association study (GWAS), such as pfarps10 (Plasmodium falciparum apicoplast ribosomal protein S10), pfkd (P. falciparum ferredoxin), and pfmdr2 (P. falciparum multidrug resistance protein 2) [17] were assessed as to whether they were also useful molecular markers for surveillance of artemisinin resistance.

Methods

Study area

The 6 sentinel sites were selected for surveillance of malaria based on the criteria described by WHO [6] which include the following considerations: population density, an area with local transmission of malaria, near the border area or direly related with border area, area with high mobile/migrant population, feasibility to conduct the study. The study area covered southern Myanmar (Kawthaung) where reduced susceptibility was first reported [4], southeast (Thanbyuzayat and Myawaddy), southern part of central Myanmar (Shwegyin), western part of central Myanmar (Magway) and western border area (Rakhine).

Study design and recruitment

For this prospective cohort study, uncomplicated falciparum malaria patients were recruited according to WHO standardized protocol [6] in 6 sentinel sites in Myanmar from 2009 to 2013 to assess the therapeutic efficacy and safety of ACT. Patients were eligible if they were aged between 2 and 65 years (except in Magway where only children under 15 years of age were recruited as the previous hospital data indicated that recurrent fever after ACT in children were not uncommon), uncomplicated falciparum mono-infection by microscopy, parasite density no more than 250,000 parasites per µL, and fever (axillary temperature ≥37.5°C) or history of fever in previous 24 h. Exclusion criteria included severe malaria, mixed species infection, non-falciparum infections, presence of other febrile diseases, regular medications that interfere with anti-malarial pharmacokinetics, history of hypersensitivity to tested anti-malarials, pregnant or lactating mothers, or unable to follow up after treatment.

Procedures

The method for surveillance of anti-malarial drug efficacy provided by WHO [6] was followed in this study. Briefly, active and passive case detection was done in the sentinel sites and if patients met the inclusion criteria, direct observed treatment with ACT was carried out. If a recruited patient vomited within 30 min after treatment, second dose was administered. A patient is enrolled and given initial treatment of ACT, then scheduled with 28 days follow-up for artether–lumefantrine and with 42 days follow-up for dihydroartemisinin–piperaquine or artesunate–mefloquine. Peripheral blood smears and a dried blood spot sample from finger pricx were taken at each of the follow ups. Clinical and blood film examination was carried out at days 0, 1, 2, 3, 7, 14, 21, 28, 35, and 42. If fever or any signs of malaria appeared within the observation period, blood film examination was carried out to exclude treatment failure. If treatment failure was observed within the observation period, an alternative ACT was prescribed.

Microscopic examination

Thick and thin blood films for parasite count were obtained and examined at screening on day 0 to confirm inclusion/exclusion criteria. Thick blood films were also examined on each follow-up visit or on any other day if the patient spontaneously returned and parasitological re-assessment was required. Parasite density was calculated by counting the number of asexual parasites against a set number of white blood cells (WBCs), typically 200–300, in thick blood film, using a hand tally counter. Parasite density, expressed as the number of asexual parasites per µL of blood, was calculated by dividing the
number of asexual parasites by the number of WBCs and then multiplying by an assumed WBC density (typically 6000 WBCs/µL). A blood slide was considered negative when the examination of 1000 WBCs did not reveal any asexual parasites.

Genotyping of malaria parasite
All treatment failure cases were genotyped as described previously [18] to differentiate a recrudescence (same parasite strain) from a newly acquired infection (different parasite strain) by analysis of the msp1, msp2 and glurp genes from the samples collected on day 0 and day of failure. Genotypic profiles of the pre- and post-parasite strains were compared.

Artemisinin resistance molecular markers analysis
The molecular marker analysis on the available 550 samples of day 0 from 6 different sentinel sites was conducted. DNA was extracted from dried blood spots by QIAamp DNA Blood Mini Kit (Qiagen, Valencia, CA) according to manufacturer's recommendation. Amplification of artemisinin resistance molecular markers, k13 (PF3D7_1343700) and other genetic foci such as pfarps10 (PF3D7_1460900.1), pfdl (PF3D7_1318100) and pfmdr2 (PF3D7_1447900) were carried out according to the procedure described previously [19, 20]. The sequences were aligned with that of 3D7 retrieved from Plasmodium database and deposited in GenBank (Accession Numbers: KX280647–KX280707).

Statistical analysis
Sample size required in each therapeutic efficacy study site was calculated based on the estimated anticipated population proportion of clinical failure rate, 15%, and precision 10% with 95% confidence level; at least 49 cases per site would be needed for analysis. For clinical follow-up data, the proportions of treatment failure and adequate clinical and parasitological response (ACPR) on day 28 or day 42, and day 3 parasite positivity after ACT, were calculated. Chi square test or Fisher’s exact tests were used to analyse the categorical data and Mann–Whitney’s U test for quantitative data. The proportion of patients who showed day 3 parasite positivity and mutations of each target genes was compared, and odds ratios (OR) were calculated. Correlation was calculated between wild type alleles for target genes and day 3 parasite positivity in each of the study sites. A significance level of 0.05 was used for all statistical tests.

Results
Therapeutic efficacy of ACT
The therapeutic efficacy study of the first-line anti-malarial in different sentinel sites (Table 1; Fig. 1) was done.
### Table 1  Summary result of therapeutic efficacy study in six sentinel sites in Myanmar (2009–2013)

| Description       | Kawthaung | Myawaddy | TBZ | Shwegyin | Rakhine | Magway |
|-------------------|-----------|----------|-----|----------|---------|--------|
| Drug              | DP        | AL       | AL  | AM       | AL      | AL     |
| Recruited cases   | 80        | 80       | 85  | 58       | 48      | 75     |
| Treatment failure | 4         | 6        | 5   | 0        | 0       | 4      |
| LFU               | 0         | 0        | 1   | 0        | 0       | 2      |
| Day 1 parasite positivity (n, %) | 76 (95.0) | 52 (65.0) | 75 (89.3) | 47 (81.0) | 40 (83.3) | 61 (82.4) |
| Day 2 parasite positivity (n, %) | 54 (67.5) | 30 (37.5) | 38 (45.2) | 12 (20.7) | 23 (47.9) | 22 (29.7) |
| Day 3 parasite positivity (n, %) | 15 (18.7) | 5 (6.3)   | 7 (8.3)   | 7 (12.1) | 5 (10.4)   | 3 (4.1)   |
| ACPR (n, %)       | 76 (95.0) | 74 (92.5) | 79 (94.0) | 58 (100.0) | 48 (100.0) | 70 (94.6) |
| Recrudescence     | 2         | 6        | 2   | 0        | 0       | 1      |
| Reinfection       | 1         | 0        | 2   | 0        | 0       | 1      |

*TBZ* Thanbyuzayat, *DP* dihydroartemisin–piperaquine, *AL* artemether–lumefantrine, *LFU* loss to follow-up, *ACPR* adequate clinical and parasitological response, *ETF* early treatment failure, *LCF* late clinical failure, *LPF* late parasitological failure
mutant rate and proportion of the C580Y mutation increased significantly from 2009 to 2013 in Kawthaung ($p < 0.0001$) (Fig. 3). When the association of individual $k13$ mutants with day 3 positivity was assessed, C469F ($p = 0.004$), N537I ($p = 0.004$), R561H ($p < 0.0001$), C580Y ($p < 0.004$), and F673I ($p = 0.01$) were significantly higher in day 3 positivity (Table 2).

**Other molecular markers**

Apart from $k13$, the sequences of $pfarps10$, $pffd$ and $pfmdr2$ that have been reported as underlying molecular markers predisposing to become $k13$ mutant associated with delayed parasite clearance after artesinin treatment, were also amplified and analysed: the mutation rate of these markers was found as $pfarps10$ (270, 49.09%), $pffd$ (322, 58.55%) and $pfmdr2$ (271, 49.27%). Geographical distribution of the previously well-known artemisinin resistance molecular markers $k13$ and newly reported markers, $pfarps10$, $pffd$ and $pfmdr2$ were similar in geographical distribution to that of day 3 parasite positivity after ACT in 6 different sentinel sites (Fig. 2). On the other hand, wild type prevalence of $k13$, $pfarps10$, $pffd$, and $pfmdr2$ was highest in the areas where there was no day 3 parasite positivity, such as Magway and Rakhine.

**Association of molecular markers with day 3 positivity after treatment**

The association of each target gene and combination of 2, 3 or 4 mutations were significantly associated with day 3 positivity (range of OR from 1.98 to 5.35). Regardless of $k13$, mutation in $pfarps10$ alone was the highest association with day 3 positivity (OR = 3.88) followed by both mutation of $pfarps10$ and $pffd$ (OR = 3.28). Furthermore, when the frequency of day 3 parasite positivity is plotted against the frequency of wild type alleles of target genes, higher mutations in the targets, $k13$ ($r = −0.9590$); $pfarps10$ ($r = −0.8840$); $pffd$ ($r = −0.6704$); and, $pfmdr2$ ($r = −0.7679$) showed lower frequency of the wild type alleles (Fig. 4).

**Discussion**

In this prospective cohort study, day 3 parasite positivity after ACT and $k13$ mutants were identified in Shwegyin (southern part of central Myanmar), Kawthaung (southern Myanmar), Thanbyuzayat, and Myawaddy (southeastern Myanmar). These findings provide strong evidence that there is a high rate of $k13$ mutants associated with day 3 parasite positivity after ACT had been distributed in Kawthaung, southern Myanmar, as early as 2009. Moreover, distribution of $k13$ mutants and day 3 parasite positivity was similar in distribution, indicating artemisinin resistance was highest in southern and southeast Myanmar. This finding reports the usefulness of newly identified genetic markers such as $pffd$, $pfarps10$ and $pfmdr2$ for surveillance of artemisinin resistance, correlating with clinical follow-up data.

Emergence and spread of artemisinin-resistant falciparum malaria has been threatening the global control of malaria [14, 21]. To know anti-malarial drug efficacy
and drug resistance, four main methods were available, composed of therapeutic efficacy study with longitudinal follow-up, in vitro drug sensitivity assay, molecular markers analysis, and anti-malarial drug concentration measurement [7].

Monitoring the efficacy of first-line or second-line ACT every 2 years in all falciparum-endemic countries was initiated by WHO to understand the proportion of day 3 parasite positivity after treatment and proportion of treatment failure by 28-day or 42-day follow-up [5]. If a treatment failure rate becomes more than 10%, it is time to review national anti-malarial treatment policy [22]. Day 3 parasite positivity after ACT treatment is of great concern as it exposes more parasites to the partner drug, potentially increasing the development of resistance to partner drugs [5]. In Myanmar, artemisinin-resistant

---

**Fig. 2** Distribution of day 3 positivity after treatment with artemisinin-based combination therapy (ACT) and molecular markers (k13, pfars10, pfdr and pfmdr2) in six sentinel sites. Day 3 prevalence and high mutant rate of molecular markers were observed in southern Myanmar sites, Myanmar Artemisinin Resistance Containment (MARC) Tier I areas.
falciparum malaria was recognized in 2009 and delayed parasite clearance was observed in all first-line anti-malarials [5, 7]. The overall efficacy of anti-malarials was 96.87% with day 3 parasite positivity of 8.0%. Interestingly, there was no case of day 3 persistence of parasitaemia after ACT in Magway (western part of central Myanmar) and Rakhine (western Myanmar).

Importantly, all recrudescence cases were detected in southern, southeast and the southern part of central Myanmar. All treatment failure cases reported from Rakhine, western Myanmar were re-infection. Moreover, ACPR was more than 90% in all sentinel sites (Table 1), and there was no evidence of decreasing ACPR. Unlike the Thai-Cambodia border areas where a study showed multi-drug-resistant falciparum malaria [23], there was low resistance of partner drugs such as mefloquine, piperaquine or lumefantrine in Myanmar [5]. Among the ACT, day 3 parasite positivity was highest in dihydroartemisinin–piperaquine group in Kawthaung, up to 18.75% in 2009. Similarly, dihydroartemisinin–piperaquine showed day 3 parasite positivity of 20.5% in Thanbyuzayat and 5.9% in Myawaddy site, while there was no day 3 parasite positivity in western Myanmar site. Furthermore, day 3 parasite positivity after dihydroartemisinin–piperaquine treatment in Shwegyin was 4.2% in 2009 and

**Table 2 Association between K13 mutations and day 3 parasite positivity**

| K13 mutation | Number of isolates | Total | P   |
|--------------|--------------------|-------|-----|
|              | Day 3 negative    | Day 3 positive |     |
| T474I        | 2                  | 0      | 2   | 1.000 |
| M476V        | 1                  | 0      | 1   | 1.000 |
| C469F        | 2                  | 4      | 6   | 0.004* |
| N490T        | 2                  | 1      | 3   | 0.365 |
| YS11H        | 1                  | 0      | 1   | 1.000 |
| G533A        | 4                  | 1      | 5   | 0.531 |
| G538V        | 5                  | 1      | 6   | 0.597 |
| N537I        | 4                  | 5      | 9   | 0.004* |
| P553L        | 0                  | 1      | 1   | 0.140 |
| ES56D        | 1                  | 0      | 1   | 1.000 |
| R561H        | 3                  | 10     | 13  | <0.0001* |
| P574L        | 14                 | 5      | 19  | 0.166 |
| C580Y        | 81                 | 24     | 105 | 0.004* |
| F673I        | 1                  | 3      | 4   | 0.010* |
| A675V        | 9                  | 0      | 9   | 0.621 |
| Total        | 130                | 55     | 185 | <0.0001* |

* Significantly associated K13 mutation with day 3 parasite positivity after treatment with ACT  
† Calculated by Chi square test and all other were calculated by Fisher’s exacted test with 95% CIs
it increased to 12.8% in 2013 suggesting potential piperaquine resistance.

Globally, molecular marker analysis has been widely used to assess the emergence and spread of drug-resistant malaria [13, 24]. After discovery of the k13 molecular marker for artemisinin resistance [25], many studies globally focused on the k13 gene [13, 25, 26]. Delayed parasite clearance, as well as k13 mutations, were reported in Cambodia [25, 28], Thailand [3, 29–31], Vietnam [32], Laos [33], southern China [34, 35], and Myanmar [9, 24]. However, more than 100 non-synonymous mutations in k13 genes of falciparum malaria parasite were reported [5, 13, 27] and all of these non-synonymous mutations were not associated with artemisinin resistance. To the best of knowledge, only Y449H, R539T, R561H, I543T, and C580Y were accepted as validated k13 mutations for artemisinin resistance and P441L, F446I, G449A, G538V, P553L, V568G, P574L and A675V as candidates markers [5]. Moreover, most of the k13 mutations were reported by cross-sectional study only. Validation of common k13 mutations by in vitro or in vivo longitudinal follow-up study to correlate delayed parasite clearance is crucial to understanding and interpreting k13 mutations in endemic areas. In the study, C469F, N537I, R561H, C580Y, and F673I were significantly associated with day 3 parasite positivity. The mutation N537I was previously observed in eastern Myanmar [9, 10], close to the Thailand border, and also in Cambodia [25]. Similarly, C469F was previously reported in Myanmar [9, 10]. Interestingly, both of these mutations observed in the Thanbyuzayat study site were geographically close to the previously identified region, Kayin State [9, 10] suggesting the mutation was contributing to artemisinin resistance in this area. Well-known validated artemisinin resistance mutation of k13, C580Y has been observed predominantly in the Kawthaung study site since 2009. The prevalence of C580Y in this study site has been increasing year by year and occupied more than 60% of isolates in 2013, indicating the increasing threat of artemisinin resistance in Kawthaung. The mutation C580Y was also found predominantly in Southeast Asian countries, including Thailand, Cambodia and Vietnam [12, 30]. The mutation F446I, predominant k13 mutation in southern China [36], northern and eastern Myanmar [10] was not observed in this study. Similarly, the mutation F673I, one of the mutations found in Southeast Asia [26] was also significantly associated with delayed parasite clearance. Evidence suggested that distinct alleles originating from independent emergence were reported rather than spread from one resistance hotspot [12], indicating the reason for occurrence of some predominant mutations in specific geographical region [27].

According to the genome-wide association study (GWAS) [17], other artemisinin resistance molecular markers were reported. In this study, the pfmdr10, pfld and pfmdr2 were studied and pfcr alleles was excluded because previous GWAS showed all isolates in Myanmar were mutant pfcr alleles. Unlike k13, all of these target genes have specific non-synonymous mutations associated with delayed clearance of parasite after

---

**Table 3** Association between single nucleotide polymorphism in target genes and day 3 parasite positivity after artemisinin combination therapy

| Target gene | SNP(s) | Odds ratio | 95% CI        | P       |
|-------------|--------|------------|---------------|---------|
| k13         | K13a   | 6.4810     | 3.4095–12.3197| <0.0001 |
| pfmdr10     | V127M  | 3.8841     | 1.9900–7.5808 | <0.0001 |
| pfld        | D193Y  | 2.8784     | 1.4456–5.7312 | 0.0018  |
| pfmdr2      | T484I  | 2.5181     | 1.3619–4.6559 | 0.0025  |
| k13 + pfmdr10 | K13 + V127M | 5.3470 | 2.919–9.7948 | <0.0001 |
| k13 + pfld  | K13 + D193Y | 4.9164 | 2.7202–8.8855 | <0.0001 |
| k13 + pfmdr2 | K13 + T484I | 4.4647 | 2.4812–8.0341 | <0.0001 |
| pfmdr10 + pfld | V127M + D193Y | 3.2796 | 1.8004–5.9742 | 0.0001  |
| pfld + pfmdr2 | V127 + T484I | 2.5541 | 1.4344–4.5478 | 0.0011  |
| k13 + pfmdr10 + pfmdr2 | K13 + V127M + T484I | 4.2245 | 2.3335–7.6479 | <0.0001 |
| k13 + pfld + pfmdr2 | K13 + D193Y + T484I | 3.4875 | 1.9084–6.3731 | <0.0001 |
| k13 + pfmdr10 + pfld | K13 + V127M + D193Y | 4.8354 | 2.6840–8.7113 | <0.0001 |
| pfmdr10 + pfld + pfmdr2 | V127M + D193Y + T484I | 2.2926 | 1.2798–4.1069 | 0.0044  |
| k13 + pfmdr10 + pfld + pfmdr2 | K13 + V127M + D193Y + T484I | 3.7588 | 2.0371–6.9356 | <0.0001 |

SNP: single nucleotide polymorphism, CI: confidence interval, ACT: artemisinin-based combination therapy

* For K13, any non-synonymous mutation in kelch propeller domain, after amino acid position 440 was analysed.
treatment. V127M of pfarps, D193Y of pfmdr2 and T484I of pfmdr2 were distributed in the same geographical regions as k13 mutations [17]. In this study, prevalence of these mutations was significantly associated with day 3 positivity after treatment with ACT. Relatively fewer rates of these mutations were observed in western Myanmar where there was no case of day 3 positivity and no k13 mutant. Moreover, individual mutations showed the association of delayed parasite clearance in pfarps10 (OR: 3.8841, p < 0.0001), pffd (OR: 2.8784, p = 0.0018), pfmdr2 (OR: 2.5181, p = 0.0025), indicating the suitability of markers for surveillance of artemisinin resistance. Similar findings of GWAS suggested pfarps10, pffd and pfmdr2 polymorphism are useful markers of genetic background on which k13 mutations are likely to appear. K13, as well as these underlying genetic foci, were also reported in asymptomatic falciparum infections [19] and migrant workers [20] in Myanmar. Surveillance of artemisinin resistance using pfarps10, pffd and pfmdr2 should be encouraged, especially for areas where no k13 mutant have been documented. Moreover, elimination of drug-resistant falciparum malaria should be encouraged with strong international endeavour to prevent the spread of drug-resistant malaria.

**Conclusions**

K13 kelch propeller mutations and higher rate of specific mutations on pfarps10 (V127M), pffd (D193Y) and pfmdr2 (T484I) in Kawthaung (southern Myanmar), Myawaddy and Thanbyuzayat (southeast Myanmar) and Shwegyin (southern part of central Myanmar), where day 3 positivity after ACT were observed. Meanwhile, a lack of both day 3 parasite positivity and k13 mutant, and low prevalence of specific mutation in pffd, pfarps10 and pfmdr2, in western Myanmar indicated artemisinin resistance has not spread or emerged in these areas. Among
the observed 15 mutations in k13, C469F, N537I, R561H, C580Y, and F673I were significantly associated with day 3 positivity after ACT. Taken together, urgent action to eliminate artemisinin-resistant parasites is needed with scaling up of regular in vivo and molecular surveillance of drug resistance, especially in western Myanmar, targeting not only k13, but also pfmdr1, pfmdr2.

Authors’ contributions
MPK, PR, MHN, and ETH contributed to study design. MHN, MTS, KTK, MMA, HWO, SSH, PZA, TTA, and NAS collected the samples, HWM, MHN and MRH performed the experiments, NNZ, CC, KT, MDB, and SG contributed to validate and analyse the data. MPK, MHN and ETH drafted the report. All authors read and approved the final manuscript.

Author details
1 Department of Medical Environmental Biology and Tropical Medicine, School of Medicine, Kankwong National University, Chunchon, Gangwon-do, Republic of Korea. 2 Department of Medical Research, Yangon, Republic of the Union of Myanmar. 3 Magway District Hospital, Ministry of Health and Sports, Magway, Republic of the Union of Myanmar. 4 World Health Organization, Geneva, Switzerland. 5 World Health Organization Country Office for Myanmar, Yangon, Republic of the Union of Myanmar. 6 World Health Organization Country Office for Thailand, Bangkok, Thailand. 7 Research Institute for Tropical Medicine, Alabang, Muntinlupa City, Philippines.

Acknowledgements
The authors thank all of the participants in this study and local health authorities from study sites for their kind help in screening, enrolling and follow-up visits. The views expressed in this article are those of the authors and do not necessarily reflect the official policies of the World Health Organization and Department of Medical Research, Republic of the Union of Myanmar. LO, KT, MDR, SG, and PR are staff members of World Health Organization. The authors alone are responsible for the views expressed in this publication and they do not necessarily represent the decisions, policy or views of World Health Organization.

Competing interests
The authors declare that they have no competing interests.

Availability of data and materials
The datasets analysed in this study are available from the research team but restrictions may apply to the availability of data, which were used under the licence of the current study, and are not publicly available. However, data are available from corresponding authors upon reasonable request and with permission of the original research team.

Consent for application
Not applicable.

Ethical approval and consents to participants
The protocol was approved by Ethical Review Committee of the Department of Medical Research, Myanmar, and Institutional Ethical Review Committee of the Kankwong National University, Korea. The study was registered with ClinicalTrials.gov, identifier NCT027092816. The written informed consent was taken from all participants. Participating in this study was entirely voluntary. Collecting, processing, handling of samples and all experiments were carried out in accordance with guidelines set and approved by Ethical Committee of the Department of Medical Research, Myanmar and Institutional Research Board of the Kankwong National University, Republic of Korea.

Funding
Therapeutic efficacy studies in the sentinel sites were supported by USAID-PMI under the World Health Organization Consolidated Grant to the Mekong region, 2008–2015. Molecular analysis was supported by the National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIP) (NRF-2014R1A2A1A11052079), and by Basic Science Research Programme through the National Research Foundation of Korea (NRF) funded by the Ministry of Science, ICT and Future Planning (2015R1A4A1038666) and Korea International Cooperation Agency (KOICA).

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Received: 12 June 2017 Accepted: 7 August 2017

References
1. WHO. Guidelines for treatment of Malaria. 3rd ed. Geneva: World Health Organization; 2015.
2. Dondorp AM, Nosten F, Yi P, Das D, Phyoh AP, Tarning J, et al. Artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med. 2009;361:455–67.
3. Phyoh AP, Nikhoma S, Stephanska K, Ashley EA, Nair S, McGready R, et al. Emergence of artemisinin-resistant malaria on the western border of Thailand: a longitudinal study. Lancet. 2012;379:1960–6.
4. Kyaw MP, Nyunt MH, Chit K, Aye MM, Aye KH, Lindegarde N, et al. Reduced susceptibility of Plasmodium falciparum to artesunate in Southern Myanmar. PLoS ONE. 2013;8:e76769.
5. WHO. Status report: artemisinin and artemisinin-based combination therapy resistance. Geneva: World Health Organization; 2016.
6. WHO. Methods for surveillance of antimalarial drug efficacy. Geneva: World Health Organization, 2009.
7. WHO. Global report on antimalarial drug efficacy and drug resistance: 2000–2010. Geneva: World Health Organization, 2010.
8. Ministry of Health. Health in Myanmar. Nay Pyi Taw; 2014.
9. Nyunt MH, Hlaing T, Oo HW, Tin-Oo L-UK, Phway HP, Wang B, et al. Molecular assessment of artemisinin resistance markers, polymorphisms in the k13 propeller and a multidrug-resistance gene in the eastern and western border areas of Myanmar. Clin Infect Dis. 2015;60:1208–15.
10. Tun KM, Imwong M, Lwin KM, Win AA, Hlaing TM, Hlaing T, Lin K, Kyaw MP, Plewes K, Faz MA, et al. Spread of artemisinin-resistant Plasmodium falciparum in Myanmar: a cross-sectional survey of the K13 molecular marker. Lancet Infect Dis. 2016;15:415–21.
11. Win AA, Imwong M, Kyaw MP, Woodrow CJ, Chotivanich K, Hanboonkunupakarn B, Pukrittayakamee S. K13 mutations and pfmr1 copy number variation in Plasmodium falciparum malaria in Myanmar. Malar J. 2016;15:110.
12. Takala-Harrison S, Jacob CG, Arze C, Cummings MP, Silva JC, Dondorp AM, et al. Independent emergence of artemisinin resistance mutations among Plasmodium falciparum in Southeast Asia. J Infect Dis. 2015;211:69.
13. Mita T, Tachibana S-I, Hashimoto M, Hirai M. Plasmodium falciparum kelch 13: a potential molecular marker for tackling artemisinin-resistant malaria parasites. Expert Rev Anti Infect Ther. 2016;14:125–35.
14. WHO. Strategy for Malaria Elimination in the Greater Mekong Subregion (2015–2030). World Health Organization Regional Office for the Western Pacific; 2015.
15. Mohon AN, Alam MS, Bayih AG, Folefoc A, Shahinas D, Haque R, Pillai DR. Mutations in Plasmodium falciparum K13 propeller gene from Bangladesh (2009–2013). Malar J. 2014;13:451.
16. Chattejee MR, Manguly S, Saha P, Bankura B, Basu N, Das M, et al. No polymorphism in Plasmodium falciparum K13 propeller gene in clinical isolates from Kolkata, India. J Pathog. 2015;2015:3:4354.
17. Miotto O, Amato R, Ashley EA, Macninis B, Almagro-Garcia J, Amarutunga C, et al. Genetic architecture of artemisinin-resistant Plasmodium falciparum. Nat Genet. 2015;47:226–34.
18. Cattanach A, Kyabajeine D, Hubbard A, Roseenthal PJ, Dorsey G. Distinguishing recrudescence from reinfection in a longitudinal antimalarial drug efficacy study: comparison of results based on genotyping of msp1, msp2, and glurp. Am J Trop Med Hyg. 2003;68:133–9.
19. Nyunt MH, Shein TZ, Zaw NN, Han SS, Muh F, Lee SK, et al. Molecular evidence of drug resistance in asymptomatic malaria infections, Myanmar, 2015. Emerg Infect Dis. 2017;23:517–20.
20. Nyunt MH, Wang B, Aye KM, Aye KH, Han J-H, Lee S-K, et al. Molecular surveillance of artemisinin resistance falciparum malaria among migrant goldmine workers in Myanmar. Malar J. 2017;16:97.
21. WHO. Global plan for artemisinin resistance containment (GPARC). Geneva: World Health Organization; 2011.
22. WHO. Emergency response to artemisinin resistance in the Greater Mekong subregion. Regional framework for action 2013–2015. Geneva: World Health Organization; 2013.
23. Amaratunga C, Lim P, Suon S, Steng S, Mao S, Sopha C, Sam B, Dek D, Try V, Amato R, et al. Dihydroartemisinin-piperaquine resistance in Plasmodium falciparum malaria in Cambodia: a multisite prospective cohort study. Lancet Infect Dis. 2016;16:57–65.
24. Ashley EA, Dhorda M, Fairhurst RM, Amaratunga C, Lim P, Suon S, Steng S, Anderson JM, Mao S, Sam B, et al. Spread of artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med. 2014;371:411–23.
25. Ariey F, Witkowski B, Amaratunga C, Beghain J, Langlois AC, Khim N, et al. A molecular marker of artemisinin-resistant Plasmodium falciparum malaria. Nature. 2014;505:50–5.
26. MalariaGEN Plasmodium falciparum Community Project. Genomic epidemiology of artemisinin resistant malaria. eLife 2016;5:e08714.
27. Ménard D, Khim N, Beghain J, Adegnika AA, Shafiul-Alam M, Amodu O, et al. A worldwide map of Plasmodium falciparum K13-propeller polymorphisms. New Engl J Med. 2016;374:2453–64.
28. Leang R, Taylor WRJ, Bouth DM, Song L, Tarning J, Char MC, et al. Evidence of Plasmodium falciparum malaria multidrug resistance to artemisinin and piperaquine in western cambodia: dihydroartemisinin–piperaquine open-label multicenter clinical assessment. Antimicrob Agents Chemother. 2015;59:4719–26.
29. Talundzic E, Okoth SA, Congpuong K, Plucinski MM, Morton L, Goldman IF, et al. Selection and spread of artemisinin-resistant alleles in Thailand prior to the global artemisinin resistance containment campaign. PLoS Pathog. 2015;11:e1004789.
30. Putaporntip C, Kuamsab N, Kosuwin R, Tantiwattanasub W, Vejakama P, Sueblinvong T, et al. Natural selection of K13 mutants of Plasmodium falciparum in response to artemisinin combination therapies in Thailand. Clin Microbiol Infect. 2016;22:285.
31. Phyoo AP, Ashley EA, Anderson TJ, Bozdech Z, Carrara VI, Srirawat K, et al. Declining efficacy of artemisinin combination therapy against P. falciparum malaria on the Thai–Myanmar border (2003–2013): the role of parasite genetic factors. Clin Infect Dis. 2016;63:784–91.
32. Thriemer K, Hong NV, Rosanas-Urgell A, Phuc BQ, Ha DM, Pockele E, et al. Delayed parasite clearance after treatment with dihydroartemisinin-piperaquine in Plasmodium falciparum malaria patients in central Vietnam. Antimicrob Agents Chemother. 2014;58:7049–55.
33. Imwong M, Jindakhad T, Kunasol C, Sutawong K, Vejakama P, Dondorp AM. An outbreak of artemisinin resistant falciparum malaria in eastern Thailand. Sci Rep. 2015;5:17412.
34. Ye R, Hu D, Zhang Y, Huang Y, Sun X, Wang J, et al. Distinctive origin of artemisinin-resistant Plasmodium falciparum on the China–Myanmar border. Sci Rep. 2016;6:20100.
35. Wang Z, Wang Y, Cabrera M, Zhang Y, Gupta B, Wu Y, et al. Artemisinin resistance at the China–Myanmar border and association with mutations in the K13 propeller gene. Antimicrob Agents Chemother. 2015;59:952–9.
36. Huang F, Takala-Harrison S, Jacob CG, Liu H, Sun X, Yang H, et al. A single mutation in K13 predominates in Southern China and is associated with delayed clearance of Plasmodium falciparum following artemisinin treatment. J Infect Dis. 2015;212:1629–35.